<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829216</url>
  </required_header>
  <id_info>
    <org_study_id>Bone marrow GvHD</org_study_id>
    <nct_id>NCT02829216</nct_id>
  </id_info>
  <brief_title>Graft-versus-host Disease Associated Myelosuppression</brief_title>
  <official_title>Functional Profiling of the Hematopoietic Stem Cell Niche in Graft Versus Host Disease Mediated Bone Marrow Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universit채t Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universit채t Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to measure the frequency, functionality and phenotype of bone marrow-derived
      mesenchymal stromal cells in patients after allogeneic hematopoietic stem cell
      transplantation. Furthermore, the immune cell infiltrate of the bone marrow will be monitored
      at the same time. These results will be correlated with the extent of cytopenia and clinical
      graft-versus-host disease grading.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the amount of mesenchymal stromal cells after allogeneic hematopoietic stem cell transplantation</measure>
    <time_frame>up to 1 year after allogeneic hematopoietic stem cell transplantation</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Abnormal Hematopoiesis</condition>
  <condition>Allogenic Disease</condition>
  <condition>Graft vs Host Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with AML/MDS receiving an allogeneic hematopoietic stem cell transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18

          -  acute myeloid leukemia

          -  myelodysplastic syndrome

          -  hematopoietic stem cell transplantation

        Exclusion Criteria:

          -  not willing to take part
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malte von Bonin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Klinik und Poliklinik I, Universit채tsklinikum, TU Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malte von Bonin, MD</last_name>
    <phone>00493514586636</phone>
    <email>malte.bonin@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I, Universit채tsklinikum, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malte von Bonin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelosuppression</keyword>
  <keyword>mesenchymal stromal cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

